Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

1.

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Simkens LH, van Tinteren H, May A, Ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M.

Lancet. 2015 Apr 7. pii: S0140-6736(14)62004-3. doi: 10.1016/S0140-6736(14)62004-3. [Epub ahead of print]

PMID:
25862517
2.

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E.

Eur J Cancer. 2015 Jan;51(1):18-26. doi: 10.1016/j.ejca.2014.10.019. Epub 2014 Nov 14.

3.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.

Eur J Cancer. 2014 Dec;50(18):3077-88.

PMID:
25459393
4.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.

PMID:
25242736
5.

[Treatment of colorectal liver metastasis at a regional hospital versus a university medical centre].

de Leur K, Huisman F, Gobardhan PD, Kint PA, Wijsman JH, Ten Tije AJ, Krause R, van Gulik TM, Rijken AM.

Ned Tijdschr Geneeskd. 2013;157(34):A6417. Dutch.

PMID:
23965247
6.

[A man with colorectal signet ring cell carcinoma: which therapy is required?].

Dietvorst MH, Schoenmakers N, ten Tije AJ.

Ned Tijdschr Geneeskd. 2013;157(20):A5507. Dutch.

PMID:
23676127
7.

The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy.

Gobardhan PD, de Wall LL, van der Laan L, ten Tije AJ, van der Meer DC, Tetteroo E, Poortmans PM, Luiten EJ.

Ann Oncol. 2013 Mar;24(3):668-73. doi: 10.1093/annonc/mds475. Epub 2012 Nov 8.

8.

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.

Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6.

9.

The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery.

Bökkerink GM, de Graaf EJ, Punt CJ, Nagtegaal ID, Rütten H, Nuyttens JJ, van Meerten E, Doornebosch PG, Tanis PJ, Derksen EJ, Dwarkasing RS, Marijnen CA, Cats A, Tollenaar RA, de Hingh IH, Rutten HJ, van der Schelling GP, Ten Tije AJ, Leijtens JW, Lammering G, Beets GL, Aufenacker TJ, Pronk A, Manusama ER, Hoff C, Bremers AJ, Verhoef C, de Wilt JH.

BMC Surg. 2011 Dec 15;11:34. doi: 10.1186/1471-2482-11-34.

10.

[Non-traumatic rupture of the spleen].

Kerckhoffs MC, Hoskam JA, ten Tije AJ.

Ned Tijdschr Geneeskd. 2011;155:A2935. Dutch.

PMID:
21486505
11.

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.

Hooker AC, Ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer E, Gelderblom H, McGuire WP, Verweij J, Karlsson MO, Baker SD.

Clin Pharmacol Ther. 2008 Jul;84(1):111-8. doi: 10.1038/sj.clpt.6100476. Epub 2008 Jan 9.

13.

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD.

J Clin Oncol. 2005 Feb 20;23(6):1070-7.

14.

Relationship of systemic exposure to unbound docetaxel and neutropenia.

Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A.

Clin Pharmacol Ther. 2005 Jan;77(1):43-53.

PMID:
15637530
15.

Factors affecting cytochrome P-450 3A activity in cancer patients.

Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A.

Clin Cancer Res. 2004 Dec 15;10(24):8341-50.

16.

Limited cerebrospinal fluid penetration of docetaxel.

ten Tije AJ, Loos WJ, Zhao M, Baker SD, Enting RH, van der Meulen H, Verweij J, Sparreboom A.

Anticancer Drugs. 2004 Aug;15(7):715-8.

PMID:
15269603
17.

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A.

Clin Pharmacol Ther. 2004 May;75(5):448-54.

PMID:
15116057
18.

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

ten Tije AJ, Smorenburg CH, Seynaeve C, Sparreboom A, Schothorst KL, Kerkhofs LG, van Reisen LG, Stoter G, Bontenbal M, Verweij J.

Eur J Cancer. 2004 Feb;40(3):352-7.

PMID:
14746852
19.

Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.

Ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, Figg WD, Sparreboom A.

Clin Pharmacol Ther. 2003 Nov;74(5):509-10. No abstract available.

PMID:
14586392
20.

Effect of valspodar on the pharmacokinetics of unbound paclitaxel.

ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A.

Invest New Drugs. 2003 Aug;21(3):291-8.

PMID:
14578679
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk